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Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are characterized
by degeneration of upper and lower motor neurons and neurons of the prefrontal
cortex. The emergence of the C9ORF72 hexanucleotide repeat expansion mutation as
the leading genetic cause of ALS and FTD has led to a progressive understanding
of the multiple cellular pathways leading to neuronal degeneration. Disturbances in
neuronal function represent a major subset of these mechanisms and because such
functional perturbations precede degeneration, it is likely that impaired neuronal function
in ALS/FTD plays an active role in pathogenesis. This is supported by the fact that
ALS/FTD patients consistently present with neurophysiological impairments prior to any
apparent degeneration. In this review we summarize how the discovery of the C9ORF72
repeat expansion mutation has contributed to the current understanding of neuronal
dysfunction in ALS/FTD. Here, we discuss the impact of the repeat expansion on
neuronal function in relation to intrinsic excitability, synaptic, network and ion channel
properties, highlighting evidence of conserved and divergent pathophysiological impacts
between cortical and motor neurons and the influence of non-neuronal cells. We
further highlight the emerging association between these dysfunctional properties with
molecular mechanisms of the C9ORF72 mutation that appear to include roles for
both, haploinsufficiency of the C9ORF72 protein and aberrantly generated dipeptide
repeat protein species. Finally, we suggest that relating key pathological observations
in C9ORF72 repeat expansion ALS/FTD patients to the mechanistic impact of the
C9ORF72 repeat expansion on neuronal function will lead to an improved understanding
of how neurophysiological dysfunction impacts upon pathogenesis.
Keywords: C9ORF72, neuron, synaptic, excitability, glutamate, physiology, ALS (amyotrophic lateral sclerosis),
FTD (frontotemporal dementia)
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INTRODUCTION
The underlying genetic and pathological causes of amyotrophic
lateral sclerosis (ALS) and frontotemporal dementia (FTD)
overlap extensively placing them on an ALS-FTD spectrum
(Kato et al., 1993; Talbot et al., 1995; Lomen-Hoerth et al.,
2002). Clinical observations of ALS-FTD patients reinforce
linked pathogenicity where almost half of ALS patients develop
FTD-related cognitive disturbances and up to 30% of FTD
patients exhibit motor impairment (Christidi et al., 2018). The
GGGGCC (G4C2) hexanucleotide repeat expansion mutation is
found within intron 1 of the C9ORF72 gene (C9ORF72 repeat
expansion, C9ORF72RE), is causal to both ALS and FTD and
is the most common pathogenic mutation within the ALS-FTD
spectrum. Degeneration is classically prominent within the pre-
frontal cortex in FTD and themotor cortex, uppermotor neurons
(layer V cortical projection neurons) and lower motor neurons in
ALS. Understanding how this mutation mechanistically leads to
neuronal injury and degeneration is of key importance.
Healthy individuals typically present with 2–30 G4C2 repeats
whereas ALS-FTD patients living with the repeat expansion
typically have hundreds to thousands of repeats, with 65 repeats
argued as the pathological repeat-length threshold (DeJesus-
Hernandez et al., 2011; Renton et al., 2011). Furthermore, they
share TDP-43 pathology that manifests in approximately 98%
of ALS patients and 45% of FTD patients (Arai et al., 2006;
Neumann et al., 2006). The repeat expansion drives pathogenicity
through at least one of two potential broad mechanisms;
haploinsufficiency of C9ORF72 protein expression and toxic
gain-of-function of the repeat expansion (Gendron et al.,
2014; Mizielinska and Isaacs, 2014). The latter can be further
subdivided into transcribed repeat expansion sense and antisense
RNA foci and aberrant non-ATG (RAN) translation leading
to the generation of five potential dipeptide-repeat proteins
(DPRs): poly-GA, -GP, -GR, -PA, and -PR (Donnelly et al., 2013;
Gendron et al., 2013; Mori et al., 2013). Attention is now focusing
on how these mechanisms drive the cellular disturbances
observed in ALS-FTD, where emerging research places emphasis
on both exclusive and synergistic mechanisms involving
haploinsufficiency and aspects of toxic-gain-of-function. Further
complexity to our understanding is contributed by the fact
we have an incomplete appreciation of the physiological role
of the C9ORF72 protein (Smeyers et al., 2021). Importantly,
several rodent models initially generated to study C9ORF72RE
mechanisms do not always recapitulate motor dysfunction
(Balendra and Isaacs, 2018), though more recent studies now
describe motor deficits in a C9ORF72 haploinsufficiency model
(Shao et al., 2019) and that motor deficits are exacerbated in a
background of both haploinsufficiency and the repeat expansion
(Zhu et al., 2020). Nonetheless, it is clear that a combination of
direct mechanisms associated with the C9ORF72RE mutation and
downstream impacted cellular processes, including prominent
neurophysiological perturbations, collectively contribute to
C9ORF72RE mediated-disease progression.
Neurophysiological dysfunction is established and prominent
within the advanced stages of neurodegenerative disease
patients where a complex combination of neuronal and
synaptic loss in addition to neuronal dysfunction leads to
a consensus systemic loss of function (Frere and Slutsky,
2018). However, in current years, the monitoring of non-
symptomatic neurodegenerative patients, including C9ORF72RE
patients, carrying familial mutations is beginning to present a
scenario whereby neurophysiological perturbations are evident
before any notable clinical symptoms arise (Benussi et al., 2016;
Geevasinga et al., 2016; Styr and Slutsky, 2018). Critically, these
perturbations present as highly plausible, core contributors to
disease pathogenesis, via neuronal injury through excitotoxicity
and reduced function by way of impaired neurotransmission.
Understanding the sources of the neurophysiological function
and mechanisms directly linking these features to the molecular
pathogenesis of the C9ORF72RE, thus have an important role
to play in understanding ALS-FTD. Typically, we consider the
general excitability of neurons to underpin its physiological
function and is ultimately dependent upon a complex myriad
of several factors including synaptic function, morphology
and altered intrinsic excitability, which is dependent upon
the functional expression of ion channels associated with
action potential generation. This review summarizes the current
literature describingC9ORF72RE-mediated neuronal dysfunction
mechanisms in both cortical and motor neurons, contrasting
these with each other as well as other ALS-FTD genetic
backgrounds. We also review how these neurons may be
impacted by other non-cell autonomous mechanisms involving
glial cells. Finally, we will discuss our current understanding
around the molecular determinants of this dysfunction and
how these are linked to haploinsufficiency and related to repeat
expansion toxic gain-of-function.





Beyond established degeneration of the motor cortex,
neurophysiological disturbances in the cortex of ALS patients
represents a longstanding pathological hallmark of disease.
Such clinical observations are consistent between both sporadic
and familial backgrounds (Geevasinga et al., 2016), including
those harboring the C9ORF72RE mutation (Williams et al., 2013;
Benussi et al., 2016; Schanz et al., 2016; Nasseroleslami et al.,
2019). Supported by extensive transcranial magnetic stimulation
(TMS) (Vucic et al., 2013; Eisen et al., 2017) and resting state
magnetoencephalography (MEG) studies (Proudfoot et al., 2016),
cortical network dysfunction in ALS patients is found to manifest
early, possibly prodromally, typically preceding lower motor
neuron dysfunction leading to a possible staged continuum
of pathogenesis consistent with a feed-forward mechanism
of neurodegeneration (Geevasinga et al., 2016; Menon et al.,
2017). Figure 1 summarizes this concept. Importantly cortical
dysfunction is not limited to ALS, it is present in FTD patients
(Lindau et al., 2003; Nishida et al., 2011) and is a common
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observation in other neurodegenerative diseases including
Alzheimer’s, Parkinson’s and Huntington’s Disease (Palop et al.,
2006; Styr and Slutsky, 2018; McColgan et al., 2020). Like for
many other neurodegenerative diseases (Selkoe, 2002), functional
synaptic perturbations at early disease stages are thought to drive
cortical synaptic loss, which correlates with severe cognitive
impairments observed in C9ORF72RE patients (Henstridge et al.,
2018). Further, magnetic resonance imaging (MRI) studies in
ALS-FTD have demonstrated structural changes in the motor
cortex that correlate with cognitive and behavioral impairments
(Agosta et al., 2016; Consonni et al., 2018), in addition to
functional defects that impact on cortical and subcortical activity
(Mohammadi et al., 2015). Cortical dysfunction is therefore
thought to play a key role in early pathogenic events in ALS-
FTD. A summary of studies investigating C9ORF72RE cortical
dysfunction is presented in Table 1.
Network and Synaptic Plasticity
Functional nervous system plasticity presents the critical ability
to modify neuronal properties in response to environmental
demands and may manifest in a number of structural and
functional changes that impact upon neurons and glial
cells (Turrigiano, 2012; Suminaite et al., 2019). Functional
impairments in plasticity are considered major early features
of neurodegenerative disease and are representative of
altered homeostasis that precedes and, potentially, drives
further neuronal dysfunction and/or loss (Milnerwood and
Raymond, 2010; Starr and Sattler, 2018; Styr and Slutsky, 2018).
Synaptic plasticity is the process by which synapses undergo
activity-dependent changes in their efficacy, where long-term
potentiation (LTP), long-term depression (LTD), and spike-time
dependent plasticity are the cellular correlates of, inter alia,
cognitive processes such as learning and memory (Malenka
and Bear, 2004). Paired associative stimulation using TMS
techniques has revealed striking LTP–like network plasticity
impairments in asymptomatic C9ORF72RE patients indicative
of early, widespread, cortical dysfunction of potential synaptic
origins (Benussi et al., 2016). Benussi et al. (2016) predict that
synaptic/network plasticity impairments present 15 years before
symptomatic onset making these pathological observations
some of the earliest evidenced in ALS-FTD patients. Direct
evidence of impaired synaptic potentiation of mini excitatory
post-synaptic currents was recently confirmed in induced
pluripotent stem cell (iPSC)-derived cortical neurons generated
from C9ORF72RE patients, a feature that was rescued in isogenic,
gene-corrected lines (Perkins et al., 2021). Beyond this, functional
investigations of impaired synaptic plasticity in ALS and FTD
have been determined in hippocampal murine preparations:
UBQLN2P497H (Gorrie et al., 2014); SOD1G93A (Spalloni et al.,
2011) and TDP-43 transgenic mice (Koza et al., 2019), TDP-43
conditional knockout mice (Wu et al., 2019). Further, impaired
hippocampal synaptic plasticity is observed in non-TDP-43 FTD
models [progranulin knock out mice (Petkau et al., 2012) and
MAPT knock out mice (Ahmed et al., 2014; Biundo et al., 2018)].
Also, impaired plasticity has been observed at the neuromuscular
junction of Drosophila over-expressing C9ORF72RE (Perry
et al., 2017). Broad cellular disruption affecting molecules and
signaling processes relevant to synaptic plasticity are highlighted
by transcriptional disturbances in both C9ORF72RE patient-
derived cortical neurons (Perkins et al., 2021) and C9ORF72RE
patient post-mortem cortex (Prudencio et al., 2015). Defined
molecular pathological mechanisms of altered cortical synaptic
plasticity in ALS-FTD remain to be elucidated. However, reduced
LTP and LTD have been demonstrated in cortico-hippocampal
connections of a murine C9ORF72 knockout model, which
highlight a role for the C9ORF72 protein in synaptic plasticity
mechanisms in the hippocampus, but also potentially suggest
that haploinsufficiency of the C9ORF72 protein may underpin
some synaptic plasticity deficits (Ho et al., 2020). Indeed, the
knockout of putative interactors with C9ORF72 also yields
notable impairments in LTP (Gerges et al., 2004; Niu et al., 2020).
Plasticity has close association with homeostatic function
and the inability to modify neuronal function in response
to external stimuli suggests that plasticity impairments may
represent very early markers of disease onset where cells are
unable to respond to, as yet unknown, chronic disease-mediated
changes (Milnerwood and Raymond, 2010; Benussi et al., 2016;
Starr and Sattler, 2018; Styr and Slutsky, 2018). Future work upon
impaired plasticity in ALS-FTD cortical neurons and circuitry
promises to yield leads into the early drivers of disease.
Cortical Hyperexcitability in Amyotrophic
Lateral Sclerosis Patients Is a Hallmark
Disease Feature
The neurophysiological profiling of ALS patients using
transcranial magnetic stimulation has revealed considerable
cortical and layer V projection neuron circuit perturbations that
are consistent with a general increase in neuronal excitability
within the motor cortex. Given these studies measure excitability
from themotor cortex, early work did not show a correlation with
(motor) cortical hyperexcitability being present in C9ORF72RE
FTD patients (Schanz et al., 2016), however, recent work has
shown that increased strength of cortical hyperexcitability in
ALS patients is associated with increased cognitive impairments
(Agarwal et al., 2021). Nonetheless, cortical hyperexcitability
has been observed in FTD models (García-Cabrero et al., 2013),
but the degree to which it plays a pathogenic role in FTD is
less understood. The observation of reduced short interval
intracortical inhibition (SICI), first reported by Kujirai et al.
(1993) in ALS patients, is highly consistent amongst sporadic and
familial cases (Geevasinga et al., 2016), including C9ORF72RE
patients (Wainger and Cudkowicz, 2015; Schanz et al., 2016;
Nasseroleslami et al., 2019), such that it is now considered a
disease hallmark. Longitudinal assessments of ALS-FTD patients
now indicate that reduced SICI manifests pre-symptomatically,
preceding lower motor neuron dysfunction (Menon et al.,
2015; Geevasinga et al., 2016) and becomes more pronounced
with disease progression (Menon et al., 2020). Cortical circuits
control upper motor neurons within the cortico-spinal tract,
and hyperexcitability is associated with excitotoxicity, therefore
cortical hyperexcitability is considered to be a pathogenic
driver of motor neuron injury and dysfunction in ALS-FTD
(Sahara Khademullah et al., 2020). Indeed, the degree of
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FIGURE 1 | Mechanisms of neurophysiological impairments in the cortex and lower motor neurons in C9ORF72RE ALS. In humans, upper motor neurons (blue)
descend from the motor cortex and project onto the brainstem and spinal cord via the corticospinal tract. These corticospinal neurons form a monosynaptic
pathway (in primates and humans) that innervates lower motor neurons (orange), which in turn transmit motor signals to effector muscles. Together this forms the
motor circuitry within humans. Neurophysiological impairments leading to ALS can arise in the corticospinal tract at various loci. In ALS, cortical dysfunction ranges
from hyperexcitability (increased excitability) as a result of increased excitatory signaling or reduced inhibition, disruption of synaptic vesicle dynamics and impaired
synaptic plasticity that also extends to cortico-hippocampal connections. Within the corticospinal tract, upper motor neurons are vulnerable to synaptic loss and
dendrite pathology including loss of dendritic spines that may arise from increased hyperexcitability. In a feedforward mechanism of dysfunction, degeneration of
lower motor neurons is mediated, at least in part, via glutamate-mediated excitotoxicity whereby, cortical dysfunction precedes that of lower motor neurons,
potentially causing further neurophysiological impairments and injury in lower motor neurons.
cortical hyperexcitability in ALS patients correlates with disease
prognosis (Shibuya et al., 2016). Understanding the physiological
and pathological determinants of cortical hyperexcitability in
ALS-FTD is a key undertaking.
Physiological mechanisms explaining early cortical
hyperexcitability are now emerging and center upon the
deregulation of the complex synchronization of excitatory
and inhibitory signaling within the cortex. Reduced cortical
SICI argues toward a reduced inhibitory influence in the
cortex of ALS-FTD patients. Accumulating evidence supports
the involvement of inhibitory GABA-ergic interneurons,
the predominant mediators of inhibitory activity in the
networked circuitry of the cortex (Farrant and Nusser, 2005),
as a pathological substrate in ALS-FTD patients. The loss of
inhibitory signaling could be mediated via the loss of function
or degeneration of interneurons thereby promoting cortical
excitability. Recent work has demonstrated a reduction in
parvalbumin interneurons, the major class of interneuron in
the motor cortex (Estebanez et al., 2017), in a TDP-43Q331K
model of ALS-FTD and C9ORF72RE ALS patient post-mortem
suggesting the loss of inhibition may well also come from a
selective vulnerability of this neuron class (Lin et al., 2021). In
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TABLE 1 | Summary of physiological studies that have implication for the C9ORF72RE in cortical dysfunction.
Cortical
neurons
Study Physiological finding Link to
C9ORF72RE
Method of investigation Model
Prudencio et al.,
2015






Decreased synaptic density associated with
cognitive decline









Jensen et al., 2020 Reduced synaptic vesicle-associated protein 2




Calcium imaging FM dye
vesicular imaging; Synaptic
protein puncta
Primary rat cortical neurons
C9ORF72RE patient-derived
iPSC cortical neurons
Perkins et al., 2021 Increased network burst activity; increased
synaptic density; impaired synaptic










The table describes the main physiological findings of the study, whether they are associated with a mechanism of C9ORF72RE pathology and upon which models these
findings were obtained.
addition to this selective vulnerability, hippocampal interneurons
appear to display considerable TDP-43 pathology in TDP-43
transgenic mice (Tsuiji et al., 2017). It may be therefore posited
that cortical interneuron dysfunction is an early contributor to
cortical hyperexcitability and that later interneuron degeneration
contributes to a more pronounced hyperexcitability as the
disease course progresses. However, to date there remains no
data to assess the function of interneurons in the context of
C9ORF72RE and our understanding must therefore be derived
via other genetic models of ALS. Selective pharmacological
rescue of cortical interneuron function in a mutant SOD1G93A
mouse model preserves motor axon function and prolonged
survival by rescuing reduced inhibitory input on to layer V
projection neurons (Sahara Khademullah et al., 2020), suggesting
that increasing interneuron function has the potential to reduce
excitability in the motor cortex, thereby being neuroprotective
to motor neurons. Although, we must also be careful in our
assessment of long range impacts of cortical activity upon
motor neuron function in ALS rodent models given that the
monosynaptic cortico-spinal tract circuit is an anatomical feature
that is exclusive to primates (Lemon, 2008). In contrast to
the former study, Kim et al. revealed parvalbumin-expressing
interneurons from neonatal and symptomatic SOD1G93A
mice had increased intrinsic excitability compared to wild-
type interneurons (Kim et al., 2017). However, data from a
TDP-43A315T mouse model (Zhang et al., 2016) showed that
young mice display sustained hyperexcitability in somatostatin-
positive interneurons, but not in parvalbumin-positive neurons,
which are hypoexcitable. Somatostatin interneurons regulate
the excitability of parvalbumin interneurons, hence the
hyperexcitability of somatostatin-expressing interneurons
drives the hypoexcitable profile of parvalbumin interneurons,
and in turn, causes hyperexcitability of the layer V projection
neurons. In addition, recent studies have demonstrated that
disturbances in the transcriptional landscape are consistent
with an impact upon inhibitory synapses in FUS1NLS/+ murine
model (Sahadevan et al., 2021; Scekic-Zahirovic et al., 2021).
Importantly, the interneuronal hypothesis also extends to
non-TDP-43 FTD forms where interneuronal pathology is
observed in murine FTD models (Lui et al., 2016) and noting
that interneurons control cortical network synchronicity, may
underlie altered EEG activity in FTD patients (Lindau et al., 2003;
Nishida et al., 2011). The underlying molecular pathological
mechanisms of interneuronal dysfunction and loss in ALS-FTD
remains to be determined.
Excitatory neurons represent approximately 80% of the
adult cortex and numerous pieces of evidence are converging
toward the contribution of these neurons to abnormalities in
cortical excitability in ALS-FTD patients. Perkins et al. (2021)
demonstrated that cultures of excitatory cortical neurons derived
from C9ORF72RE iPSCs displayed an enhanced network burst
frequency compared to control derived neurons. These properties
appear to be explained by the fact that C9ORF72RE excitatory
neurons had an increased functional synaptic input due to
increased synaptic density, but not altered intrinsic excitability.
Interestingly, an increased synaptic input of excitatory cortical
neurons was seen in the motor cortex of pre-symptomatic (at
postnatal day 30) mutant TDP-43Q331K mice and SODG93A mice
(Van Zundert et al., 2008; Fogarty et al., 2016a; Saba et al.,
2016). Given that iPSC-derived cortical neurons are likely to
reflect a physiologically early developmental status (Livesey et al.,
2016) and that murine models show early disturbances, it is
possible these studies are in line with an emerging consensus
of increased excitatory synaptic activity as being a feature
of cortical hyperexcitability. Importantly, this consensus may
extend to other neurodegenerative diseases, such as Alzheimer’s
Disease, where increased excitatory synaptic density and input
early in disease is again observed in equivalent models (Šišková
et al., 2014; Ghatak et al., 2019). Nonetheless, there are reports
of excitatory input not changing in the TDP-43A315T model
(Zhang et al., 2016) and a C9ORF72RE murine model, though
this latter model does not display classical ALS-FTD pathology
or neurodegeneration (Peters et al., 2015). Increased synaptic
density in ALS-FTD is in clear contrast to the belief that
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neurodegeneration causes synaptic loss. Indeed, the degree of
synaptic loss in the pre-frontal cortex of C9ORF72RE ALS-FTD
patient post-mortem correlates with the degree of cognitive
impairment displayed by the patients (Henstridge et al., 2019).
Furthermore, later stage, symptomatic P60 TDP-43A315T mice
exhibit layer V projection neurons with a decrease in synaptic
input and spine density (Handley et al., 2017). These collective
latter studies are therefore consistent with a trend that synaptic
loss is restricted to latter stages of the disease course and
accompanies the onset of symptomatic disease. The data would
therefore suggest a shift from an early increased synaptic density
property of C9ORF72RE excitatory cortical neurons, supporting
cortical hyperexcitability observations, to a general decrease,
which appear to be aligned to symptomatic onset.
Mechanisms promoting cortical synaptic density remain
unreported but are associated with transcriptional dysregulation
consistent with modified expression of synaptic architecture
proteins (Prudencio et al., 2015; Perkins et al., 2021). Conversely,
mechanisms supporting synaptic loss in C9ORF72RE cortical
neurons are now emerging. Synaptic loss is observed in the
prefrontal cortex of aged (4.5 months) transgenic mice expressing
80-repeat GR (GR80) DPRs (Choi et al., 2019). Furthermore,
consistent with increasing reports of C9ORF72 localization at
the synapse (Frick et al., 2018; Xiao et al., 2019), hippocampal
regions of 3-month old C9ORF72 knockout mice show a
reduction in synaptic density (Xiao et al., 2019), suggesting
that haploinsufficiency may play a role in cortical synaptic loss.
C9ORF72 is also highly expressed in microglia (Rizzu et al.,
2016), and recent work has determined that loss of C9ORF72
exacerbates microglial synaptic pruning activity in the cortex,
which correlates with cognitive impairments (Lall et al., 2021).
Synaptic loss may therefore be driven by perturbed microglial
function driven through C9ORF72 haploinsufficiency. Noting
that microglia can equally sense and be regulated by neuronal
excitability (Umpierre and Wu, 2021), how microglia contribute
to cortical hyperexcitability or are potentially influenced by
hyperexcitability will be a key question to resolve in how ALS-
FTD progresses.
Layer V Projection Neurons Display
Hyperexcitability and Morphological
Defects
Layer V cortical projection neurons (aka upper motor neurons)
are a vulnerable population in ALS that functionally connect the
motor cortex to lower motor neuron populations in the spinal
cord. Reduced inhibition onto layer V neurons appears to drive
hyperexcitability in this neuronal population in TDP-43A135T
mice (Zhang et al., 2016). Recent data from a rodent model in
which hyperexcitability is chronically chemogenetically driven
in upper motor neurons leads to the development of essential
features of ALS, including upper and lower motor neuron
degeneration, reactive gliosis and induced TDP-43 pathology
(Haidar et al., 2021). Such data is consistent with the interrelation
between hyperexcitability and the feed forward model of
neurodegeneration. Furthermore, it appears that increased
hyperexcitability can generate morphological changes. A study
upon a nuclear localization sequence-deficient mouse model
of TDP-43 identified that cytoplasmic mislocalization of TDP-
43 drives intrinsic hyperexcitability and decreased excitatory
synaptic inputs (Dyer et al., 2021). Indeed, hyperexcitability may
drive continued functional synaptic loss, dendritic spine loss and
dendrite pathology in upper motor neurons that are commonly
observed features in upper motor neurons of ALS patient post-
mortem tissue (Hammer et al., 1979; Genç et al., 2017) and other
models, includingTDP-43A315T (Handley et al., 2017), SOD1G93A
(Fogarty et al., 2016b, 2017), and FUSR521G (Sephtona et al.,
2014). Clearly, data on C9ORF72RE remains scant for this cell
type. Future work will be required to clarify whether impairments
in layer V projection neurons are determined by intrinsic, cell
autonomous mechanisms and/or are driven by altered input
via cortical dysfunction which in turn drives hyperexcitability
and synaptic loss.




Disease progression in neurodegenerative diseases is thought to
reflect a stage of homeostatic adaptation, where disease-driven
disturbances in network function are functionally tolerated for
an undetermined period of time, but ultimately give way to
network failure, where homeostasis mechanisms cannot viably
maintain function (Frere and Slutsky, 2018). There is potential
evidence for functional changes in ALS-FTD models that may
reflect this early shifting landscape. Longitudinal assessment
of synaptic and intrinsic excitability of SOD1G93A layer V
cortical projections reveal a fluctuating reciprocal profile of
altered intrinsic excitability and synaptic input that could
reflect functional adaptation at the pre-symptomatic stage (Kim
et al., 2017). Similarly, despite C9ORF72RE iPSC-derived cortical
neurons exhibiting increased synaptic density, consistent with
increased excitability (and burst frequency), neurons also display
a reduced readily releasable pool of synaptic vesicles. As a result,
these neurons display a reduced ability to maintain synaptic
transmission and present a reduced burst duration (Perkins
et al., 2021). These latter data are consistent with a putative
role of C9ORF72 protein in vesicular trafficking within the
trans-Golgi network (Snowden et al., 2012; Aoki et al., 2017;
Frick et al., 2018) and that C9ORF72 haploinsufficiency may
result in a reduction of the readily releasable pool of vesicles.
Consistent with these data, mice engineered to express 149-
repeat GA (GA149) DPRs also demonstrate a reduced expression
of synaptic vesicle protein SV2 in addition to altered Ca2+
homeostasis and impaired vesicle release in cortical neurons
(Jensen et al., 2020). In this regard, such reductions in general
vesicular function may potentially reflect early homeostatic
adaptations in response to increased synaptic density (or vice
versa) driven by pathological C9ORF72RE-related mechanisms.
Interestingly, potential modifiers of disease onset in C9ORF72RE
FTD-mediated disease appear to be associated with altered
expression of proteins with synaptic roles including synaptic
vesicle dynamics (Barbier et al., 2021). Given that cortical
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function can be readily monitored in patients, establishing the
earliest known physiological disturbances in cortical function
in C9ORF72RE and the pathological drivers underpinning this
may give us one of our earliest windows into understanding
C9ORF72RE disease onset and progression.




In receiving monosynaptic innervation from upper motor
neurons, lower spinal motor neurons represent the final
effector component of the lower motor system, whose axons
project to innervate skeletal muscle fibers (Burke, 1981). Lower
motor neuron dysfunction has long been an established
clinical observation, detected by nerve conduction and
electromyography (EMG) and are key criteria in the diagnosis
of ALS (Daube, 1985; Mogyoros et al., 1998; Geevasinga et al.,
2015; de Carvalho and Swash, 2016) including C9ORF72RE
patients (Geevasinga et al., 2015). Critically, altered lower
motor neuron function in ALS patients is evidenced after
that of cortical dysfunction and parallels the onset of patients
developing muscle weakness, atrophy, fasciculation and cramps
in ALS (Menon et al., 2015). Further, the development of
fasciculation and cramps precede that of muscle weakness
suggesting that hyperexcitability leading to progressive loss of
function (hypoexcitability) is a feature of the lower motor neuron
in ALS disease progression before eventual degeneration and loss
(Bae et al., 2013). In this aspect of the review, we will discuss the
mechanisms leading to the potential changes in excitability and
neurophysiological mechanisms leading to excitotoxicity and cell
death. These studies are summarized in Table 2.
Loss of Synaptic Innervation From Upper
Motor Neurons
Synaptic glutamatergic signaling links upper and lower motor
neuron function, and, glutamate-mediated excitotoxicity
is considered one of the main pathogenic mechanisms
that contributes to the degeneration of motor neurons
in ALS-FTD (Cleveland and Rothstein, 2001). The
hypothesis is multifaceted and includes cell autonomous
and non-cell autonomous mechanisms. Commensurate
with cortical disease progression, synaptic loss in lower
motor neurons is an established observation in the latter
stages of ALS and is expected to be a major physiological
determinant preventing lower motor neuron function
in the later stages of disease (Sasaki and Maruyama,
1994). Synaptic loss accompanied by CREB-dependent
transcriptomic and proteomic changes is observed in
C9ORF72RE iPSC-derived motor neurons maintained for
extended culture time (Catanese et al., 2021). A number
of hypotheses center upon disturbances in glutamate-
mediated signaling and altered excitability being major
contributors to synaptic loss and other sites of lower
motor neuron injury.
Lower motor neurons are responsive to synaptic glutamate
via the synaptic expression of glutamatergic AMPA and NMDA
receptors (Van Den Bosch et al., 2006). Early work determined an
apparent intrinsic vulnerability of lower motor neurons to AMPA
receptor-mediated excitotoxicity (Rothstein et al., 1990, 1992;
Couratier et al., 1993; Rothstein, 1995; Cleveland and Rothstein,
2001). Elevated synaptic glutamate levels are predicted given
the increased excitability of upper motor neurons. However,
whether pre-synaptic terminal deficits in glutamate release
from upper motor neurons exist remains to be determined.
Nonetheless, the uptake of glutamate from the synaptic cleft is
strongly hypothesized to be reduced given that the expression
of astrocyte glutamate transporter (EAAT2) is widely reported
to be attenuated in multiple ALS models (Rosenblum and
Trotti, 2017). In the case of C9ORF72RE however, patient-
derived astrocytes are not consistent with a reduction in
EAAT2 expression or function (Allen et al., 2019b; Zhao et al.,
2020). How such data are to be reconciled with other ALS
models of glutamate transporter dysfunction and expression
remains to be resolved.
Over stimulation of glutamate receptors gives rise to
the possibility of an injurious, excitotoxic level of Ca2+
influx (Pina-Crespo et al., 2014) and iPSC-derived motor
neurons obtained from C9ORF72RE patients exhibit enhanced
vulnerability to glutamate receptor-mediated excitotoxicity
(Donnelly et al., 2013; Selvaraj et al., 2018; Shi et al., 2018; Bursch
et al., 2019). Interestingly, this vulnerability has been rescued
pharmacologically in studies using an anticoagulation-deficient
form of activated protein C (Shi et al., 2019) and antisense
oligonucleotides against the repeat expansion (Donnelly et al.,
2013).Mechanistically, this vulnerability has been shown to occur
as a result of increased relative expression of Ca2+ permeable
AMPA receptors in C9ORF72RE patient-derived motor neurons
due to a greater expression of Ca2+ permeable AMPA receptor
subunit GluA1 (Selvaraj et al., 2018; Shi et al., 2018; but
see Moore et al., 2019). Further work on C9ORF72RE patient
post-mortem demonstrated that the dysregulation of GluA1
is selective to C9ORF72RE lower motor neurons and is not
present in the cortex, and thus providing an example of
a regional specific degenerative mechanism (Selvaraj et al.,
2018; Gregory et al., 2020). The dysregulation of GluA1 also
appears conserved amongst other genetic ALS backgrounds
including mutant TDP-43 motor neurons (Bursch et al., 2019),
FUS (Udagawa et al., 2015) and in sporadic ALS patients,
where the latter show further dysregulation of AMPA receptor
subunits in the cortex (Gregory et al., 2020). In agreement,
data from mSOD1 patients and models indicate a converging
mechanism of vulnerability to glutamate-mediated excitotoxicity
via Ca2+ permeable AMPA receptors (Shaw, 2005; Van Den
Bosch et al., 2006), where such studies appear consistent with
a reduction in the relative expression of GluA2 subunits, the
master regulators of Ca2+ permeability. The GluA2 subunit
achieves this because it predominantly presents in its post-
transcriptionally edited form where a channel-lining, positively
charged arginine side chain protrudes into the ion channel,









































TABLE 2 | Summary of physiological studies that have implication for the C9ORF72RE in lower motor neuron dysfunction.
Lower motor neurons Study Physiological finding Link to
C9ORF72RE
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TABLE 2 | (Continued)
Lower motor neurons Study Physiological finding Link to
C9ORF72RE
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presenting a charge block to Ca2+ flux (Traynelis et al.,
2010) whereas, the pre-edited GluA2 form contains a non-
charged glutamine side chain and permits Ca2+ flux. Notably,
inefficient RNA editing of the GluA2 subunit, thus resulting in
Ca2+-permeability, has been reported in sporadic ALS patient
samples (Kawahara et al., 2004a,b). However, whilst appearing
to impact upon the function of editing enzyme ADAR2, this
mechanism does not appear to be the source of increased Ca2+-
permeable AMPA receptors in C9ORF72RE patients (Selvaraj
et al., 2018; Moore et al., 2019). Mechanisms of GluA1
upregulation in the context of C9ORF72RE has been associated
with haploinsufficiency of C9ORF72 protein in lower motor
neurons derived from patient iPSCs and C9ORF72 knockout
mice (Shi et al., 2018) and also hippocampal neurons (Xiao
et al., 2019). In support of this, the knockout of putative
C9ORF72 interactor Rab39b in primary neuron culture results
in increased GluA1 trafficking to dendrites (Mignogna et al.,
2015, 2021). Interestingly, despite early work indicating the
low impact of NMDA receptor-mediated excitotoxicity on
motor neurons, recent studies have shown an upregulation
of the NMDA receptor subunit GluN1 (Shi et al., 2018) that
can be rescued along with GluA1 upregulation using small
molecule inhibitors of phosphatidylinositol-5-kinase signaling
(Staats et al., 2019). The role of NMDA receptors in glutamate-
mediated excitotoxicity and the role of DPRs remains to be fully
explored. However, recent Drosophila models presenting poly-
GR and PR (GR36, PR36) constructs demonstrated an increase
in NMDA receptor-mediated signaling in glutamatergic neurons,
suggesting that DPRs may have a role in the dysregulation of
glutamate receptors in C9ORF72RE motor neurons (Xu and Xu,
2018).
Clearly, a strong emphasis of research thus far has been given
to the perturbations associated with glutamatergic signaling. The
disruption of inhibitory GABA-ergic and glycinergic signaling
in the spinal tract has been implicated in ALS, largely in
mSOD1 models (Martin and Chang, 2012), though initial
reports indicated this was a secondary event to motor neuron
degeneration (Hossaini et al., 2011). Though, more recent
work in SOD1G93A mice now implicates deficits in inhibitory
signaling associated with V1 interneurons in the spinal tract that
parallel motor disturbances, raising the possibility that increased
excitatory signaling in ALS patients may also stem from a
reduced impact of inhibitory influences (Allodi et al., 2021).
The specific impact of the C9ORF72RE mutation on inhibitory
signaling whether in the cortex or lower motor neuron remains
to be determined.
Altered Excitability in Lower Motor
Neurons
Altered motor neuron excitability in C9ORF72RE patients
is predicted to be underpinned by changes in intrinsic
expression of ion channels that support action potential
conduction (Geevasinga et al., 2015). Physiological mechanisms
addressing lower motor neuron excitability in the context
of C9ORF72RE have been widely investigated in vitro,
employing iPSC-derived motor neurons from C9ORF72RE
ALS patient fibroblasts. Patch-clamp studies have reported
hyperexcitability at early stages of motor neuron differentiation
(2–6 weeks in culture) where cells become intrinsically more
excitable to depolarization (Devlin et al., 2015; Wainger and
Cudkowicz, 2015). However, as cultures are maintained
further (7–10 weeks), they become hypoexcitable, evidenced
by a reduction in action potential generation in response
to depolarization compared to motor neurons derived
from healthy patients (Sareen et al., 2013; Zhang et al.,
2013; Devlin et al., 2015; Naujock et al., 2016; Guo et al.,
2017). No changes in cell survival were reported in these
studies, which supports the idea that changes in excitability
are early signs of functional loss of motor neurons prior
to their degeneration, which is also supported by clinical
studies of motor function in ALS patients (Iwai et al., 2016).
Furthermore, these data are broadly consistent with the
overall consensus nature of shifting excitability in mutant
SOD1 mice motor neurons that display a period of early
hyperexcitability before hypoexcitability (Leroy and Zytnicki,
2015), which in turn precedes motor neuron denervation
(Martínez-Silva et al., 2018).
Key mechanisms that drive these excitability states are now
emerging. Selective tuning of cortical inhibition in SOD1G93A
mice to reduce potential cortical hyperexcitability has a protective
impact upon lower motor neurons (Sahara Khademullah et al.,
2020), suggesting that early hyperexcitability in lower motor
neurons, at least in part, is driven by upstream cortical
and upper motor neuron dysfunction and may drive injury
or further pathological processes. On this note, increased
depolarization of motor neurons, including via glutamate, has
the ability to promote the formation of TDP-43 pathology
(Weskamp et al., 2020) and drive DPR formation (Westergard
et al., 2019). Interestingly, more recent data using improved
iPSC-derived MN protocols yielding enriched, predominant
neuronal cultures with very little glial differentiation does not
exhibit any consistent differences in motor neuron excitability
(Selvaraj et al., 2018; Zhao et al., 2020). This discrepancy
from previous studies appears to be resolved by the fact that
co-cultures of motor neurons with C9ORF72RE astrocytes are
induced to be hypoexcitable and that previous studies used
protocols with heterogeneous cellular specification including
astrocytes (Zhao et al., 2020). Beyond other impacts upon
motor neuron health (Serio et al., 2013; Meyer et al., 2014;
Allen et al., 2019a), the roles of astrocytes are therefore
likely to play critical non-cell autonomous roles in the
modulation of motor neuron excitability. This mechanism
may be related to a soluble transmissible factor given that
cultures of murine motor neurons with conditioned medium
derived from SOD1G93A expressing astrocytes, was found to
alter ion channel function and motor neuron excitability
(Fritz et al., 2013). Furthermore, recent data implicate a
decreased expression of astrocyte KIR4.1-containing ion channels
to adequately remove potassium extruded from active motor
neuron axons in mSOD1models indicating possible mechanisms
impacting the ability of astrocytes to adequately maintain axonal
homeostasis (Kelley et al., 2018). It therefore appears that
numerous cell autonomous and non-autonomous mechanisms
are at play here and not limited to intrinsic lower motor
neuron processes.
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TABLE 3 | Summary of the main physiological observations that are associated with ALS.
Physiological observation Evidence in non-C9ORF72RE ALS-FTD Evidence in C9ORF72RE ALS-FTD
Patient cortical
hyperexcitability
Established as a hallmark observation in ALS, including
sporadic (reviewed Geevasinga et al., 2016). Evidenced
pre-symptomatically (Geevasinga et al., 2016; Menon et al.,
2017), and prominence increases with disease onset (Menon
et al., 2020).
Evidenced in FTD patients (Lindau et al., 2003; Nishida et al.,
2011) and associated with cognitive decline.
Motor cortical hyperexcitability evidenced in C9ORF72RE ALS
(Williams et al., 2013; Benussi et al., 2016; Schanz et al., 2016;
Nasseroleslami et al., 2019).
Increased strength of cortical hyperexcitability observed in
ALS-FTD patients correlates with increased cognitive
impairments (Agarwal et al., 2021).
Altered neuronal plasticity Hippocampal synaptic plasticity was evidenced in murine
models: UBQLN2P497H (Gorrie et al., 2014); SOD1G93A
(Spalloni et al., 2011); TDP-43 transgenic mice (Koza et al.,
2019), TDP-43 conditional knockout mice (Wu et al., 2019);
non-TDP-43 FTD models (progranulin knock out mice (Petkau
et al., 2012) and MAPT knockout (Ahmed et al., 2014; Biundo
et al., 2018).
Patient synaptic/network plasticity observations are present in
presymptomatic disease stages (Benussi et al., 2016).
Synaptic plasticity defects are highlighted in iPSC-derived
C9ORF72RE cortical neurons (Perkins et al., 2021) and
C9ORF72RE postmortem cortex (Prudencio et al., 2015).
Impaired plasticity at the neuromuscular junction of C9ORF72RE




Increase in synaptic input and intrinsic excitability in murine
models of SOD1G93A (Kim et al., 2017).
Reduction in cortical interneurons in TDP-43Q331K knock-in
mouse (Lin et al., 2021).
Cortical hyperexcitability observed in FTDP-17 mouse model of
FTD (García-Cabrero et al., 2013).
Elevated network burst activity and enhanced synaptic input
was found in iPSC-derived C9ORF72RE cortical neurons, linked
with decreased synaptic density, but not altered intrinsic
excitability (Perkins et al., 2021).
TDPA315T mouse model show sustained hyperexcitability in
somatostatin-positive interneurons, but hypoexcitability in
parvalbumin-positive neurons (Zhang et al., 2016).
Increased synaptic input of excitatory cortical neurons was
evidenced in the motor cortex of pre-symptomatic mutant
TDP-43Q331K mice and SODG93A mice (Van Zundert et al.,
2008; Fogarty et al., 2016a; Saba et al., 2016).
Presymptomatic excitability changes in ALS models reviewed in
Gunes et al., 2020.
Post-symptomatic cortical
neurophysiological function
Decreased in synaptic input in ALS post-mortem tissue
(Hammer et al., 1979; Genç et al., 2017) and other models,
including TDP-43A315T (Handley et al., 2017), SOD1G93A
(Fogarty et al., 2016b, 2017), and FUSR521G (Sephtona et al.,
2014).
Synaptic loss was found to correlate with cognitive decline
(Henstridge et al., 2018; Lall et al., 2021).
Synaptic loss was observed in the prefrontal cortex of aged
(4.5 months) transgenic mice expressing 80-repeat GR (GR80)
DPRs (Choi et al., 2019).
TDP-43 mouse model shows intrinsic hyperexcitability and
decreased excitatory synaptic inputs (Dyer et al., 2021).
Hippocampal regions of 3-month-old C9ORF72 knockout mice
show a reduction in synaptic density (Xiao et al., 2019).
Symptomatic TDP-43A315T mice exhibit layer V projection
neurons with a decrease in synaptic input and spine density
(Handley et al., 2017).
Post-symptomatic excitability changes in ALS models reviewed
in Gunes et al. (2020).
Patient lower motor neuron
excitability
Axonal hyperexcitability and decreased function with
symptomatic onset was reported in sporadic ALS patients
(Geevasinga et al., 2015).
Increased motor unit excitability, increased presence of
fasciculation potentials, single unit motor unit firing, increased
axonal excitability (reviewed in Gunes et al., 2020).
Increased axonal excitability has been highlighted in
symptomatic C9ORF72RE ALS patients (Geevasinga et al.,
2015).
Models of lower motor
neuron intrinsic excitability
Evidence of early hyperexcitability was seen in mSOD1 models
(reviewed in Gunes et al., 2020).
Evidence of hyperexcitability at early stages of motor neuron
differentiation (Devlin et al., 2015; Wainger and Cudkowicz,
2015) switching to hypoexcitability with culture time (Sareen
et al., 2013; Devlin et al., 2015; Zhang et al., 2015; Naujock
et al., 2016; Guo et al., 2017).
(Continued)
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TABLE 3 | (Continued)
Physiological observation Evidence in non-C9ORF72RE ALS-FTD Evidence in C9ORF72RE ALS-FTD
Shifting excitability in mutant SOD1 mice motor neurons that
display a period of early hyperexcitability before hypoexcitability
(Leroy and Zytnicki, 2015) preceding motor neuron denervation
(Martínez-Silva et al., 2018).
SOD1G93A expressing astrocytes was found to alter ion channel
function and motor neuron excitability (Fritz et al., 2013).
Increased excitability via pharmacological inhibition of small
conductance calcium-activated potassium (SK) channels
promotes survival and restores the activity-dependent
transcriptional profiles and synaptic composition in
iPSC-derived C9ORF72RE motor neurons, and furthermore,
promotes locomotor function in a Drosophila model containing
36 hexanucleotide repeats (Castelli et al., 2021; Catanese et al.,
2021).
Loss of motor neuron
synaptic input
Synaptic changes in ALS models reviewed in Gunes et al.
(2020).
Decreased synaptic activity and spontaneous post-synaptic
current activity was evidenced in iPSC-derived C9ORF72RE
motor neurons (Devlin et al., 2015).
Loss of NMJ function and
innervation
mTDP-43 Drosophila shows synaptic vesicle cycling defects
(Coyne et al., 2017).
C9ORF72RE Drosophila over-expressing hexanucleotide
repeats (58- and 30-repeats) exhibit impaired synaptic release
at the neuromuscular junction and decrease in number of active
zones (Freibaum et al., 2015; Zhang et al., 2015).
Decreased synaptic arborization and active zone number at
neuromuscular junction in C9ORF72RE patient-derived motor
neurons (Perry et al., 2017).
Impaired vesicle dynamics that precede motor neuron loss have
been evidenced in GA mouse model and C9ORF72RE
patient-derived motor neurons (Jensen et al., 2020).
Glutamate excitability mSOD1 patients and models exhibit vulnerability to
glutamate-mediated excitotoxicity (Shaw, 2005; Van Den
Bosch et al., 2006).
C9ORF72RE patient-derived iPSC motor neurons exhibit
enhanced vulnerability to glutamate receptor-mediated
excitotoxicity (Donnelly et al., 2013; Selvaraj et al., 2018; Shi
et al., 2018; Bursch et al., 2019).
C9ORF72RE post-mortem demonstrated that the dysregulation
of GluA1 is selective to C9ORF72RE lower motor neurons and is
not present in the cortex (Selvaraj et al., 2018; Gregory et al.,
2020).
GluA1 dysregulation is evidenced in mutant TDP-43 motor
neurons (Bursch et al., 2019), FUS (Udagawa et al., 2015) and
in sporadic ALS patients (Gregory et al., 2020).
Inefficient RNA editing of GluA2 subunits in sporadic ALS
patients (Kawahara et al., 2004a).
The table details the prominent pathophysiological concepts that are thought to play a role in the pathogenesis of ALS; for example, cortical hyperexcitability and glutamate
dysfunction in lower motor neurons. We summarize papers that provide data in non-C9ORF72RE models and contrast these in current C9ORF72RE models.
The rescue of both hypoexcitability and hyperexcitability
in motor neurons has been a pharmacological target in
recent years. The promotion of increased excitability via
pharmacological inhibition of small conductance calcium-
activated potassium (SK) channels promotes survival and
restores the activity-dependent transcriptional profiles and
synaptic composition in C9ORF72RE iPSC-derived motor
neurons, and furthermore, promotes locomotor function in
a Drosophila model containing 36 hexanucleotide repeats
(Castelli et al., 2021; Catanese et al., 2021). C9ORF72RE motor
neurons also demonstrated an increase in the expression
of SK channel subunits, which could be corrected using
specific inhibition of the SRSF1-dependent nuclear export
of pathological C9ORF72RE transcripts (Castelli et al., 2021).
Contrastingly, hyperexcitability in lower motor neurons has
been established in several other ALS models and studies
have used pharmacological activators of Kv7 potassium ion
channels to reduce hyperexcitability in C9ORF72RE-derived
motor neurons with the possibility that they protect motor
neurons from excitotoxicity (Wainger et al., 2014; Huang et al.,
2021). These studies have now been translated into clinical trials
(Wainger et al., 2021). Our current understanding of the shifting
excitability in both cortical and motor neurons indicates that the
pharmacological benefit of modulators of excitability to patients
will need to be understood and carefully considered according
to disease stage.
Impaired Neurotransmitter Release Is a
Feature of the Neuromuscular Junction
in Amyotrophic Lateral Sclerosis
Motor neuron denervation from the neuromuscular junction
precedes motor neuron loss. Given that motor activity is
required for the maintenance of innervation, it is no surprise
that loss of motor neuron pre-synaptic activity is associated
with disease pathogenesis. Measurable loss of motor input is
common to symptomatic ALS patients and consistent with
pre-synaptic dysfunction of motor neurons (Maselli et al., 1993)
that is observed primarily, and more aggressively, in association
with neuromuscular junctions innervated by fast-twitch motor
neurons in SOD1G93A mice (Cappello and Francolini, 2017).
Beyond rodent models, reduced synaptic function has now
been observed in several other models including Drosophila and
zebrafish (Cappello and Francolini, 2017; Butti et al., 2021).
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Studies in fly models overexpressing hexanucleotide repeats
(58 and 30 repeats) demonstrate impaired synaptic release at
the neuromuscular junction and a reduced number of active
zones in motor neurons (Freibaum et al., 2015; Zhang et al.,
2015). Consistent with a reduction in synaptic activity over
time, spontaneous post-synaptic current activity was shown
to progressively decrease in C9ORF72RE iPSC-derived motor
neurons and was directly associated with hypoexcitability, but
not motor neuron loss (Devlin et al., 2015). The potential for
impaired synaptic release may be therefore related to an inherent
inability to generate sufficient action potential activity at the
pre-synaptic terminal. Moreover, Jensen and colleagues recently
reported aberrations in vesicle dynamics that coincide with the
loss of vesicle protein SV2 and precede motor neuron loss in a
poly-GA (GA149) animal model and C9ORF72RE motor neurons
(Jensen et al., 2020). Interestingly, such observations align with
investigations in cortical neurons and suggests that not only do
poly-GA repeats interfere with the synaptic release mechanism
but also the reduction in vesicular dynamics in the cortex may
have mechanistic overlap with motor neurons (Jensen et al.,
2020). This study also reports that altered vesicle dynamics are
associated with elevated Ca2+ influx, which controls synaptic
vesicular release (Jensen et al., 2020). It has therefore been
hypothesized that the increased cytoplasmic Ca2+ may form a
homeostatic mechanism to potentially rescue synaptic release.
Indeed, the pharmacological rescue of C9ORF72RE model
(GR100) via the induction of endogenous NMJ plasticity signaling
can rescue synaptic function (Perry et al., 2017). Moreover,
Coyne et al. report that synaptic vesicle cycling defects due to
deficits in the post-transcriptional inhibition of Hsc70-4/HSPA8
expression are common to C9ORF72RE andmTDP-43Drosophila
models (Coyne et al., 2017), suggesting that vesicle depletion is
at play at the NMJ. Importantly, this mechanism is linked to
dynamin function, a key player in axonal transport, and therefore
suggests that synaptic vesicle impairments and established
impairments in axonal transport in ALS are potentially linked
(Gunes et al., 2020).
SUMMARY
Our review provides an overview of the key concepts of
neurophysiological disturbances in C9ORF72RE-mediated
ALS-FTD. We have provided details on the current
mechanistic view of the sources of these perturbations,
when these appear in disease and allude to their relevance
to pathogenesis. Many aspects of neurophysiological
dysfunction in the context of C9ORF72RE-mediated disease
are currently inferred. In this respect, a general consensus
of early cortical hyperexcitability progressing to general
loss of function consistent with hypoexcitability in the
symptomatic period appears to be consistent across patients
and, importantly, several ALS-FTD models appear to replicate
this progression, at least in aspects (summarized in Table 3).
However, there are established examples of mechanistic
disturbances that differ from other genetic backgrounds.
Similarly, pathogenesis of cortical and motor dysfunction
display overlapping dysfunctional features but also selective
regional differences.
Current models of C9ORF72RE are broad, and are known to
have both advantages and disadvantages especially in regards
to their inability to fully capture the disease phenotype (Sances
et al., 2016; Balendra and Isaacs, 2018). New improvements
in disease modeling are needed to forward our understanding
of disease pathogenesis and progress is now being made in
this respect. For example, the ability to model the cortico-
spinal tract in vitro in a human context is now documented
(Andersen et al., 2020) and furthermore, it is now possible to
examine the impact of native length DPR species in Drosophila
(West et al., 2020). Importantly, the development of C9ORF72RE
rodent models that successfully recapitulate major aspects of
ALS-FTD remains ongoing (Balendra and Isaacs, 2018). Such
tools will allow us to systematically define the mechanistic
impact of the C9ORF72RE on cell types, as well as cell types
upon each other.
In this regard, neurophysiological disturbances in ALS-FTD
are now much more complex than previously believed. Beyond
multiple molecular mechanisms associated with the C9ORF72RE,
disturbances are likely to have an additional non-cell autonomous
component relating to other dysfunctional cell-types that now
include astrocytes and microglia. It is also becoming clear
that for all neurodegenerative disease early functional changes
may partially reflect homeostatic mechanisms that counteract
disease-driven pathophysiology. On this note, emerging work
is now beginning to consider the cortico-spinal circuit as a
singular functional unit and this work will allow us to identify
how each component can potentially impact each other. Such
data will help stratify early mechanisms associated with disease
progression for potential pharmacological benefit. Finally, we
must consider that neurophysiological impairments may be
causal to, or as a result of, a myriad of other equally known
disease processes that include mitochondrial dysfunction, axonal
transport dysregulation, impaired proteostasis and aberrant RNA
metabolism. Although future studies have much to elucidate, it is
now clear that altered neurophysiological function inC9ORF72RE
ALS-FTD plays a key role in the pathogenesis of the disease.
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